Relationship Between Plasma Aripiprazole and Dehydroaripiprazole Concentrations and Prolactin Levels in Chinese Children and Adolescents
- 1 February 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Child and Adolescent Psychopharmacology
- Vol. 33 (1), 27-33
- https://doi.org/10.1089/cap.2022.0068
Abstract
Objective: To investigate the relationship between plasma aripiprazole (ARI) and its metabolite dehydroaripiprazole (DARI) concentrations and prolactin (PRL) levels in Chinese children and adolescents. Methods: This was a retrospective cross-sectional study and the data were collected at Beijing HuiLongGuan Hospital, a Beijing City owned psychiatric hospital, between January 1 and December 31, 2021. Fifty-two child and adolescent inpatients (17 males, 35 females) aged 13–18 years and received ARI regardless of diagnosis were included. The steady-state ARI and DARI plasma concentrations were measured using high-performance liquid chromatography-tandem mass spectrometry. The serum PRL levels were measured by chemiluminescence immunoassay. Results: The plasma concentrations of ARI, DARI, and the total of ARI and DARI were negatively correlated with serum PRL levels in female children and adolescents. Approximately 15% of child and adolescent inpatients treated with ARI exhibited subnormal PRL serum levels. Conclusions: The results suggest that in addition to regularly monitoring PRL levels, therapeutic drug monitoring for ARI and its main metabolite DARI can help to mitigate the adverse medical consequences associated with PRL reduction. Thus, clinicians should consider the ARI-induced reduction of PRL levels when prescribing ARI to child and adolescent patients, particularly among females.Keywords
This publication has 31 references indexed in Scilit:
- Adjunctive Aripiprazole Versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled TrialsPLOS ONE, 2013
- Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: A case seriesPsychiatry and Clinical Neurosciences, 2010
- Acute Treatment of Pediatric Bipolar I Disorder, Manic or Mixed Episode, With AripiprazolePublished by Physicians Postgraduate Press, Inc ,2009
- An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct DisorderJournal of Child and Adolescent Psychopharmacology, 2009
- A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled Study of Oral Aripiprazole for Treatment of Adolescents With SchizophreniaAmerican Journal of Psychiatry, 2008
- Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric DisordersJournal of Clinical Psychopharmacology, 2008
- A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) studyEuropean Psychiatry, 2007
- Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust PharmacologyNeuropsychopharmacology, 2003
- Dopamine as a Prolactin (PRL) InhibitorEndocrine Reviews, 2001
- Hypoprolactinemia as Related to Seminal Quality and Serum TestosteroneArchives of Andrology, 1989